Neuralstem's spinal cord delivery platform will get the academic treatment, as the company has licensed the stem cell technology for research at Cedars-Sinai Medical Center in Los Angeles. With Neuralstem's floating cannula device, the platform is the first of its kind to deliver stem cells directly into the gray matter of the spinal cord. The platform is currently in Phase I trials, and the FDA has already assigned it orphan status for the treatment of Lou Gehrig's disease, giving Neuralstem 7 years of exclusivity in the market. Release